Julia Gavrilyuk
Overview
Explore the profile of Julia Gavrilyuk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
345
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ladror D, Gu C, Tong V, Schammel A, Gavrilyuk J, Haight A, et al.
Drug Metab Dispos
. 2023 Dec;
52(2):135-142.
PMID: 38050039
Antibody-drug conjugates (ADC) have gained momentum for treatment of cancers, with 14 ADCs currently approved for commercial use worldwide. Calicheamicin is one of the payloads contributing to this trend, being...
2.
Wiedemeyer W, Gavrilyuk J, Schammel A, Zhao X, Sarvaiya H, Pysz M, et al.
Mol Cancer Ther
. 2022 Jun;
21(6):986-998.
PMID: 35642431
In the past year, four antibody-drug conjugates (ADC) were approved, nearly doubling the marketed ADCs in oncology. Among other attributes, successful ADCs optimize targeting antibody, conjugation chemistry, and payload mechanism...
3.
Nicolaou K, Rigol S, Pitsinos E, Das D, Lu Y, Rout S, et al.
Proc Natl Acad Sci U S A
. 2021 Jun;
118(25).
PMID: 34155147
Antibody-drug conjugates (ADCs) have emerged as valuable targeted anticancer therapeutics with at least 11 approved therapies and over 80 advancing through clinical trials. Enediyne DNA-damaging payloads represented by the flagship...
4.
Nicolaou K, Pan S, Pulukuri K, Ye Q, Rigol S, Erande R, et al.
J Org Chem
. 2021 Feb;
86(4):3377-3421.
PMID: 33544599
Molecular design, synthesis, and biological evaluation of tubulysin analogues, linker-drugs, and antibody-drug conjugates are described. Among the new discoveries reported is the identification of new potent analogues within the tubulysin...
5.
Nicolaou K, Rekula S, Kumar S, Podilapu A, Matuszak R, Jung P, et al.
J Org Chem
. 2021 Jan;
86(3):2499-2521.
PMID: 33417458
Thailanstatin A and spliceostatin D, two naturally occurring molecules endowed with potent antitumor activities by virtue of their ability to bind and inhibit the function of the spliceosome, and their...
6.
Holte D, Lyssikatos J, Valdiosera A, Swinney Z, Sisodiya V, Sandoval J, et al.
Bioorg Med Chem Lett
. 2020 Oct;
30(24):127640.
PMID: 33127540
PNU-159682 is a highly potent secondary metabolite of nemorubicin belonging to the anthracycline class of natural products. Due to its extremely high potency and only partially understood mechanism of action,...
7.
Nicolaou K, Krieger J, Murhade G, Subramanian P, Dherange B, Vourloumis D, et al.
J Am Chem Soc
. 2020 Aug;
142(36):15476-15487.
PMID: 32852944
Taking advantage of the -symmetry of the antitumor naturally occurring disorazole B molecule, a symmetrical total synthesis was devised with a monomeric advanced intermediate as the key building block, whose...
8.
Nicolaou K, Li R, Chen Q, Lu Z, Pitsinos E, Schammel A, et al.
J Am Chem Soc
. 2020 Jul;
142(29):12890-12899.
PMID: 32662641
Our previous studies with shishijimicin A resulted in the total synthesis of this scarce marine natural product and a number of its simpler analogues endowed with picomolar potencies against certain...
9.
Nicolaou K, Shelke Y, Dherange B, Kempema A, Lin B, Gu C, et al.
J Org Chem
. 2020 Feb;
85(5):2865-2917.
PMID: 32065746
Despite previous studies within the epothilone field, only one member of this compound family, ixabepilone, made it to approval for clinical use. Recent advances in organic synthesis and medicinal chemistry...
10.
Nicolaou K, Das D, Lu Y, Rout S, Pitsinos E, Lyssikatos J, et al.
J Am Chem Soc
. 2020 Jan;
142(5):2549-2561.
PMID: 31976660
The family of anthraquinone-fused enediyne antitumor antibiotics was established by the discovery of dynemicin A and deoxy-dynemicin A. It was then expanded, first by the isolation of uncialamycin, and then...